Advanced in Mantle Cell Lymphoma (MCL)

Huiqiang Q. Huang

Raoping Rd, 
Shantou, CN 
Advanced in Mantle Cell Lymphoma (MCL)
Raoping Rd, 
Shantou, CN 
OverviewLocationsClinical Research

Overview

Huiqiang Huang practices in Shantou, China. Huang is rated as an Advanced expert by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Their top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Peripheral T-Cell Lymphoma, and Agranulocytosis.

Their clinical research consists of co-authoring 112 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 11 articles and participated in 1 clinical trial in the study of Mantle Cell Lymphoma (MCL).

Locations

Raoping Rd, Shantou, 515041, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: LOXO-305
Study Phase: Phase 2
A Phase 1/2, Open-label, Multi-center Study to Evaluate theSafety and Efficacy of Selinexor Combined With Chemotherapy orTislelizumab in Relapsed or Refractory Mature T and NK Cell Lymphoma
A Phase 1/2, Open-label, Multi-center Study to Evaluate theSafety and Efficacy of Selinexor Combined With Chemotherapy orTislelizumab in Relapsed or Refractory Mature T and NK Cell Lymphoma
Enrollment Status: Terminated
Publish Date: January 05, 2026
Intervention Type: Combination product
Study Drugs: Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

111 Total Publications

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: October 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Huang's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile